Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE

Inclusion Criteria: * Documented HIV-1 infection * Treatment naive or experienced * Self-reported illicit substance use or confirmed urine drug screen within past 6 months of any of the following: cocaine, heroin, methamphetamine, MDMA, phencyclidine, ketamine, gamma hydroxybutyrate, cathiniones, or inappropriate prescription opiate, benzodiazepine or stimulant use (excluding nicotine, alcohol, marijuana for criteria) * HIV RNA \>1000 copies/mL * Creatinine clearance \> 30 mL/min (Cockroft-Gault) * ALT and AST \< 5 times the upper limit of normal * Willing and able to provide written informed consent Exclusion Criteria: * History of integrase or tenofovir related HIV resistance mutations * Pregnancy * Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry